View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSinopharm Tech Holdings 配当と自社株買い配当金 基準チェック /06Sinopharm Tech Holdings配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 24Sinopharm Tech Holdings Limited, Annual General Meeting, Jan 15, 2025Sinopharm Tech Holdings Limited, Annual General Meeting, Jan 15, 2025, at 11:00 China Standard Time. Location: units 1302-3, 13/f, ruttonjee house, ruttonjee centre, 11 duddell street, central, Hong Kongお知らせ • Dec 02Sinopharm Tech Holdings Limited to Report Fiscal Year 2024 Results on Dec 12, 2024Sinopharm Tech Holdings Limited announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Dec 12, 2024お知らせ • Feb 20Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024Sinopharm Tech Holdings Limited announced that they will report first half, 2024 results on Feb 29, 2024お知らせ • Dec 30Sinopharm Tech Holdings Limited Announces Management ChangesThe board of directors of Sinopharm Tech Holdings Limited announced that with effect from 29 December 2023. Mr. CHAU Wai Wah Fred has tendered his resignation as the executive Director due to his other personal engagements. In replacement of Mr. CHAU, Ms. KWOK Shuk Yi, the executive Director, and Mr. HO Kam Kin, the executive Director, have been appointed as the Compliance Officer. The Board further announced that with effect from 29 December 2023: Mr. CHAU has resigned as the member of the remuneration committee of the Company and nomination committee of the Company; Mr. HEUNG Pik Lun, the independent non-executive Director, has been appointed as a member of the Remuneration Committee; and Ms. KWOK, the executive Director, has been appointed as a member of the Nomination Committee.お知らせ • Nov 23Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023, at 11:00 China Standard Time. Location: Units 13023, 13/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong Central Hong Kong Agenda: To receive and consider the audited consolidated financial statements, the directors' report and independent auditors' report of the Company for the year ended 30 June 2023; to consider and re-elect Mr. CHAU Wai Wah Fred as an executive director; to consider and re-elect Mr. LAU Fai Lawrence as an independent non-executive director; to consider and re-elect Mr. HSU Dong An as an independent non-executive director; to consider and re-elect Mr. HEUNG Pik Lun as an independent non-executive director; to consider and re-appoint Elite Partners CPA Limited as auditors of the Company and to authorize the Board to fix their remuneration; and to transact such other business matters.お知らせ • Nov 04Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023Sinopharm Tech Holdings Limited announced that they will report Q1, 2024 results on Nov 14, 2023お知らせ • Sep 23Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023Sinopharm Tech Holdings Limited provides earnings guidance for the year ended 30 June 2023. The Group is expected to record the loss attributable to equity holders of the Company for the year ended 30 June 2023 to decrease in the range between 80% and 90%, as compared with the loss attributable to equity holders of the Company of approximately HKD 88.0 million for the year ended 30 June 2022. The significant decrease in loss was mainly attributable to, among other things, (i) gain on disposal of locked-up shares related to profit guarantee; (ii) gain on settlement of loans by shares issued; (iii) less impairment losses on goodwill; and (iv) the company having strengthened its efforts in cost control, resulting in less administrative and operating expenses.お知らせ • Sep 21Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023Sinopharm Tech Holdings Limited announced that they will report fiscal year 2023 results at 4:00 PM, China Standard Time on Sep 29, 2023お知らせ • Sep 17Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination CommitteeThe board of directors of Sinopharm Tech Holdings Limited announced that Mr. HEUNG Pik Lun (Mr. HEUNG) has been appointed as an independent non-executive Director of the company and a member of the audit committee and the nomination committee of the company with effect from 15 September 2023. Mr. HEUNG Pik Lun, aged 61, is a senior executive with extensive experience in administrative management. With over 20 years of business experience in both China and Hong Kong, Mr. HEUNG has a wealth of experience in market development. He has also managed several listed companies in China and Hong Kong, demonstrating a deep understanding and proficient skills in corporate management and capital market. He holds a Royal Chartered Surveyor qualification.決済の安定と成長配当データの取得安定した配当: YB2の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: YB2の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Sinopharm Tech Holdings 配当利回り対市場YB2 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (YB2)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Hospitality)3.0%アナリスト予想 (YB2) (最長3年)n/a注目すべき配当: YB2は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: YB2は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: YB2の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: YB2が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/09 20:13終値2023/09/13 00:00収益2023/06/30年間収益2023/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sinopharm Tech Holdings Limited これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 24Sinopharm Tech Holdings Limited, Annual General Meeting, Jan 15, 2025Sinopharm Tech Holdings Limited, Annual General Meeting, Jan 15, 2025, at 11:00 China Standard Time. Location: units 1302-3, 13/f, ruttonjee house, ruttonjee centre, 11 duddell street, central, Hong Kong
お知らせ • Dec 02Sinopharm Tech Holdings Limited to Report Fiscal Year 2024 Results on Dec 12, 2024Sinopharm Tech Holdings Limited announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Dec 12, 2024
お知らせ • Feb 20Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024Sinopharm Tech Holdings Limited announced that they will report first half, 2024 results on Feb 29, 2024
お知らせ • Dec 30Sinopharm Tech Holdings Limited Announces Management ChangesThe board of directors of Sinopharm Tech Holdings Limited announced that with effect from 29 December 2023. Mr. CHAU Wai Wah Fred has tendered his resignation as the executive Director due to his other personal engagements. In replacement of Mr. CHAU, Ms. KWOK Shuk Yi, the executive Director, and Mr. HO Kam Kin, the executive Director, have been appointed as the Compliance Officer. The Board further announced that with effect from 29 December 2023: Mr. CHAU has resigned as the member of the remuneration committee of the Company and nomination committee of the Company; Mr. HEUNG Pik Lun, the independent non-executive Director, has been appointed as a member of the Remuneration Committee; and Ms. KWOK, the executive Director, has been appointed as a member of the Nomination Committee.
お知らせ • Nov 23Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023, at 11:00 China Standard Time. Location: Units 13023, 13/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong Central Hong Kong Agenda: To receive and consider the audited consolidated financial statements, the directors' report and independent auditors' report of the Company for the year ended 30 June 2023; to consider and re-elect Mr. CHAU Wai Wah Fred as an executive director; to consider and re-elect Mr. LAU Fai Lawrence as an independent non-executive director; to consider and re-elect Mr. HSU Dong An as an independent non-executive director; to consider and re-elect Mr. HEUNG Pik Lun as an independent non-executive director; to consider and re-appoint Elite Partners CPA Limited as auditors of the Company and to authorize the Board to fix their remuneration; and to transact such other business matters.
お知らせ • Nov 04Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023Sinopharm Tech Holdings Limited announced that they will report Q1, 2024 results on Nov 14, 2023
お知らせ • Sep 23Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023Sinopharm Tech Holdings Limited provides earnings guidance for the year ended 30 June 2023. The Group is expected to record the loss attributable to equity holders of the Company for the year ended 30 June 2023 to decrease in the range between 80% and 90%, as compared with the loss attributable to equity holders of the Company of approximately HKD 88.0 million for the year ended 30 June 2022. The significant decrease in loss was mainly attributable to, among other things, (i) gain on disposal of locked-up shares related to profit guarantee; (ii) gain on settlement of loans by shares issued; (iii) less impairment losses on goodwill; and (iv) the company having strengthened its efforts in cost control, resulting in less administrative and operating expenses.
お知らせ • Sep 21Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023Sinopharm Tech Holdings Limited announced that they will report fiscal year 2023 results at 4:00 PM, China Standard Time on Sep 29, 2023
お知らせ • Sep 17Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination CommitteeThe board of directors of Sinopharm Tech Holdings Limited announced that Mr. HEUNG Pik Lun (Mr. HEUNG) has been appointed as an independent non-executive Director of the company and a member of the audit committee and the nomination committee of the company with effect from 15 September 2023. Mr. HEUNG Pik Lun, aged 61, is a senior executive with extensive experience in administrative management. With over 20 years of business experience in both China and Hong Kong, Mr. HEUNG has a wealth of experience in market development. He has also managed several listed companies in China and Hong Kong, demonstrating a deep understanding and proficient skills in corporate management and capital market. He holds a Royal Chartered Surveyor qualification.